California Public Employees Retirement System held its stake in shares of NewLink Genetics Corp (NASDAQ:NLNK) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,300 shares of the biotechnology company’s stock at the close of the second quarter. California Public Employees Retirement System owned 0.06% of NewLink Genetics worth $135,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of NLNK. First Trust Advisors LP lifted its position in NewLink Genetics by 11.1% in the 2nd quarter. First Trust Advisors LP now owns 28,598 shares of the biotechnology company’s stock worth $210,000 after buying an additional 2,859 shares during the last quarter. Wells Fargo & Company MN lifted its position in NewLink Genetics by 1.8% in the 2nd quarter. Wells Fargo & Company MN now owns 165,791 shares of the biotechnology company’s stock worth $1,219,000 after buying an additional 2,865 shares during the last quarter. Trexquant Investment LP lifted its position in NewLink Genetics by 39.1% in the 2nd quarter. Trexquant Investment LP now owns 18,132 shares of the biotechnology company’s stock worth $133,000 after buying an additional 5,097 shares during the last quarter. Northern Trust Corp lifted its position in NewLink Genetics by 4.0% in the 2nd quarter. Northern Trust Corp now owns 298,738 shares of the biotechnology company’s stock worth $2,195,000 after buying an additional 11,532 shares during the last quarter. Finally, Federated Investors Inc. PA lifted its position in NewLink Genetics by 20.0% in the 2nd quarter. Federated Investors Inc. PA now owns 73,076 shares of the biotechnology company’s stock worth $537,000 after buying an additional 12,168 shares during the last quarter. 52.66% of the stock is owned by institutional investors.

Shares of NewLink Genetics Corp (NASDAQ:NLNK) opened at $8.86 on Monday. NewLink Genetics Corp has a 12-month low of $5.90 and a 12-month high of $25.17.

In related news, major shareholder Stine Seed Farm, Inc. acquired 780,487 shares of the stock in a transaction on Friday, October 6th. The stock was purchased at an average price of $10.25 per share, for a total transaction of $7,999,991.75. Following the completion of the transaction, the insider now owns 7,857,732 shares of the company’s stock, valued at approximately $80,541,753. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 13.70% of the company’s stock.

A number of analysts recently weighed in on NLNK shares. ValuEngine downgraded NewLink Genetics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Jefferies Group set a $7.00 target price on NewLink Genetics and gave the stock a “hold” rating in a research report on Friday, August 25th. Cantor Fitzgerald restated a “buy” rating and issued a $26.00 target price on shares of NewLink Genetics in a research report on Friday, September 8th. Bank of America started coverage on NewLink Genetics in a research report on Friday, October 13th. They issued a “buy” rating and a $22.00 target price for the company. Finally, Zacks Investment Research downgraded NewLink Genetics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $23.43.

ILLEGAL ACTIVITY NOTICE: This article was published by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.watchlistnews.com/newlink-genetics-corp-nlnk-holdings-maintained-by-california-public-employees-retirement-system/1742736.html.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Want to see what other hedge funds are holding NLNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewLink Genetics Corp (NASDAQ:NLNK).

Institutional Ownership by Quarter for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.